Hyperparathyroidism News and Research

RSS

Hyperparathyroidism is a condition in which the parathyroid gland (one of four pea-sized organs found on the thyroid) makes too much parathyroid hormone. This causes a loss of calcium from the bones and an increased level of calcium in the blood. Symptoms include bone pain and kidney problems.

In most cases doctors don't know the cause. The vast majority of cases occur in people with no family history of the disorder. Only about 5 percent of cases can be linked to an inherited problem. Familial multiple endocrine neoplasia type 1 is a rare, inherited syndrome that affects the parathyroids as well as the pancreas and the pituitary gland. Another rare genetic disorder, familial hypocalciuric hypercalcemia, is sometimes confused with typical hyperparathyroidism. Each accounts for about 2 percent of primary hyperparathyroidism cases.

In the United States, about 100,000 people develop the disorder each year. Women outnumber men two to one, and risk increases with age. In women 60 years and older, two out of 1,000 will develop hyperparathyroidism each year.

KAI Pharmaceuticals to receive manufacturing services from Formatech

Today, Formatech announced that they have selected KAI Pharmaceuticals, Inc. and their KAI-4169 compound as the second clinical candidate to receive Formatech’s manufacturing services under its Fillanthropy Program.

18 Nov 2009

DaVita to demonstrate clinical outcomes, patient care and nutrition through 43 abstracts

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), in conjunction with DaVita Clinical Research®, today announced that company representatives will deliver 43 abstracts—40 posters and three oral presentations—at this year’s American Society of Nephrology’s (ASN) Renal Week to be held in San Diego, Calif., from Oct. 27 – Nov. 1, 2009.

24 Oct 2009

Validus chooses Ranbaxy to market an authorized generic version of Rocaltrol in the US

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), Gurgaon, India, announced an agreement with Validus Pharmaceuticals LLC (Validus) to market and distribute an authorized generic version of Rocaltrol(R) (calcitriol) in both softgel capsules and an oral liquid formulation. Overall market sales for calcitriol softgel capsules and oral liquid were $70 million (IMS - MAT: June 2009).

2 Sep 2009

New Australian health programmes provide health checks for children and teen dental care

Three new health programmes for children and teenagers have been announced by the Australian Federal Government which include a $150 voucher for teenage dental care, free health checks for children starting school and a guide to kids' health for parents.

2 Jul 2008

Vitamin D linked to reduced mortality rate in chronic kidney disease

For patients with moderate to severe chronic kidney disease (CKD), treatment with activated vitamin D may reduce the risk of death by approximately one-fourth, suggests a study in the August Journal of the American Society of Nephrology.

7 May 2008

Minimally invasive parathyroidectomy under local/sedation

Parathyroidectomy is the removal of one or more of the parathyroid glands to treat hyperparathyroidism (abnormal over-functioning of the parathyroid glands).

18 Sep 2007

Obesity linked to hyperparathyroidism in chronic kidney disease

For patients with chronic kidney disease (CKD), the risk of elevated levels of parathyroid hormone (PTH), or hyperparathyroidism a significant complication that increases the risk of cardiovascular problems and death increases along with body weight, reports a study in the September Clinical Journal of the American Society of Nephrology.

9 Aug 2007

Bariatric surgery - possible treatment for type 2 diabetes mellitus

What role could bariatric surgery possibly play as a treatment for type 2 diabetes mellitus? This topic and several others will be discussed at the American Association of Clinical Endocrinologists (AACE) Sixteenth Annual Meeting & Clinical Congress, Thursday, April 12, 2007 at the Washington State Convention & Trade Center in Seattle.

5 Apr 2007

AUA podium session on stone disease

2-phase randomized crossover study on a constant diet with calcium carbonate supplementation at 250 mg 4 times daily.

13 Jun 2006

Dialysis patients may be overmedicated

Changes in a widely used assay (blood test) for parathyroid hormone (PTH) have made its use with the established guidelines for end stage renal disease clinical management both inappropriate and potentially harmful to patients. This research is published in the journal Seminars in Dialysis.

5 Dec 2005

Bone Care International issued new patent

Bone Care International has announced that the U.S. Patent and Trademark Office has issued to it U.S. Patent Number 6,903,083 entitled "Stabilized hydroxyvitamin D."

8 Jun 2005

Cinacalcet drug more successful than a placebo in treating hyperparathyroidism

Research led by Saint Louis University physicians has shown that a new drug can help control one of the most common side effects of kidney disease.

29 Apr 2004

Cinacalet helps control overactive thyroids, a major complication of advanced kidney disease

A new drug can help control an overactive thyroid, a major complication of advanced kidney disease, by playing a trick on the gland, a new study finds. The drug, cinacalet, is much more effective at keeping the parathyroid gland working normally than a placebo, according to the study. It may be a good alternative to standard therapy, researchers said.

7 Apr 2004

Phase 3 study of drug teduglutide in patients with short bowel syndrome

Teduglutide is an analog of glucagon-like peptide 2 (GLP-2), a naturally occurring hormone that regulates the growth, proliferation and maintenance of cells lining the gastrointestinal tract. Teduglutide has been shown in animal studies and previous human clinical trials to increase the size and number of these cells, thereby increasing the absorptive surface area of the intestines.

6 Apr 2004